ARTICLE | Finance
Watch and wait
Buysiders’ dim views of the big caps heading into 2018
January 6, 2018 12:47 AM UTC
Heading into 2018, buysiders expressed more concerns than optimism about former darlings in the large cap tier.
WBB Securities’ John Nolan, ClearBridge Investments’ Marshall Gordon and AXA Investment Managers’ Linden Thomson are following patent litigation and cardiovascular outcomes data for hypercholesterolemia drug Praluent alirocumab from Regeneron Pharmaceuticals Inc. and Sanofi, but they remain pessimistic on the PCSK9 inhibitor’s commercial prospects...